Politics, Policy & Law

Article


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">Congress relying on flawed model to set drug pricing policy</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1ef7l34r60">CBO model ignores impact on preclinical biotechs, underestimates effects of price controls on drug development</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Steve Usdin, Washington Editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Harvard Business School

Biotechnology Innovation Organization

Congress relying on flawed model to set drug pricing policy

A CBO model ignores impacts on preclinical biotechs and underestimates the effects of price controls on drug development.

CBO model ignores impact on preclinical biotechs, underestimates effects of price controls on drug development

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>